Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Author:

Hoelzer Dieter1,Walewski Jan2,Döhner Hartmut3,Viardot Andreas3,Hiddemann Wolfgang4,Spiekermann Karsten4,Serve Hubert1,Dührsen Ulrich5,Hüttmann Andreas5,Thiel Eckhard6,Dengler Jolanta7,Kneba Michael8,Schaich Markus9,Schmidt-Wolf Ingo G. H.10,Beck Joachim11,Hertenstein Bernd12,Reichle Albrecht13,Domanska-Czyz Katarzyna2,Fietkau Rainer14,Horst Heinz-August8,Rieder Harald15,Schwartz Stefan6,Burmeister Thomas6,Gökbuget Nicola1

Affiliation:

1. Department of Internal Medicine II, Hematology and Oncology, University Hospital, Frankfurt, Germany;

2. Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;

3. Department of Internal Medicine III, University Hospital, Ulm, Germany;

4. Department of Medicine III, Clinic Grosshadern, Munich, Germany;

5. Department of Hematology and Oncology, University Hospital, Essen, Germany;

6. Department of Hematology, Oncology, and Tumorimmunology, Charité Campus Benjamin Franklin, Berlin, Germany;

7. Department of Internal Medicine V, University of Heidelberg, Germany;

8. Department of Internal Medicine II, University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany;

9. Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany;

10. Department of Internal Medicine III, University of Bonn, Bonn, Germany;

11. Department of Medicine II, University Hospital, Mainz, Germany;

12. Department of Internal Medicine I, Clinic Bremen-Mitte, Bremen, Germany;

13. Department of Hematology/Oncology, University Hospital, Regensburg, Germany;

14. Institute for Radiotherapy, University Hospital, Erlangen, Germany; and

15. Institute for Human Genetics, University Clinic, Duesseldorf, Germany

Abstract

Key Points Largest prospective trial for adult Burkitt lymphoma/leukemia patients. Substantial cure rates and high treatment-realization rates in all age groups.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3